Lipophilic-polycationic delivery systems

• US 6,005,004 A
• Filed: 06/07/1995
• Issued: 12/21/1999
• Est. Priority Date: 08/05/1994
• Status: Expired due to Fees

• Current Assignee: Molecular / Structural Biotechnologies Incorporated
• Original Assignee: Molecular / Structural Biotechnologies Incorporated
• Inventors: Tomoaia-Cotisel, Maria, Katz, Robert
• Primary Examiner(s): Smith, Lynette R. F.
• Assistant Examiner(s): LEE, DATQUAN HUU
• Application Number:
  US08/487,693
• Time in Patent Office: 1,658 Days
• Field of Search: 514/549, 514/6, 514/552, 514/8, 514/558, 514/12, 514/560, 514/21, 424/DIG. 7, 424/420, 424/78.31, 424/426, 424/450, 424/94.3, 424/94.2, 530/327, 435/174, 435/180, 435/181, 435/182
• US Class Current: 514/549
• CPC Class Codes: A61K 47/542 Carboxylic acids, e.g. a fatty acid or an amino acid
• CPC Class Codes: A61K 47/6415 Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
• CPC Class Codes: A61K 47/645 Polycationic or polyanionic oligopeptides, polypeptides or polyamino acids, e.g. polylysine, polyarginine, polyglutamic acid or peptide TAT

Abstract

The present invention describes site-specific biomolecular complexes comprising a therapeutic, prophylactic and diagnostic agent, called also biologically active molecule and an omega-3 fatty acid and derivatives thereof. The complexes are further covalently bonded with cationic carriers and permeabilizer peptides for delivery across the blood-brain barrier and with targeting moieties for uptake by target brain cells. Said complexes are particularly useful for delivery of a biologically active agent to the glial tissue of the brain as well as to the cortical, cholinergic and adrenergic neurons. The preferred therapeutic complexes or conjugates comprise an omega-3 fatty acid such as alpha-linolenic acid, eicosapentaenoic acid or docosahexaenoic acid and derivatives thereof.

Claims

1. A lipophilic biomolecular complex comprising:

a) a polycationic carrier selected from the group consisting of poly-lysine, poly-arginine and poly-ornithine containing a minimum of 5 monomeric amino acid units and wherein said polycationic carrier has 2-20 eicosapentaenoic acid moieties attached to the terminal amino or guanidino groups of their constitutive monomers, b) a biologically active agent and c) one or more additional eicosapentaenoic acid moieties.

2. The biomolecular complex of claim 1 wherein said polycationic carrier has 5 to 50 amino acid residues.

3. The biomolecular complex of claim 1 wherein said biologically active agent is selected from the group consisting of peptides, polypeptides, proteins, enzymes, hormones, growth factors, antigens, antibodies, and polyethylene glycol-derivatized proteins.

4. The biomolecular complex of claim 2 wherein said biologically active agent is selected from the group consisting of peptides, polypeptides, proteins, enzymes, hormones, growth factors, antigens, antibodies, and polyethylene glycol-derivatized proteins.

5. The biomolecular complex of claim 1 wherein said biologically active agent is selected from the group consisting of nucleic acids, oligonucleotides and transfection vectors.

6. The biomolecular complex of claim 2 wherein said biologically active agent is selected from the group consisting of nucleic acids, oligonucleotides and transfection vectors.

7. The biomolecular complex of claim 1 wherein said biologically active agent is selected from the group consisting of drugs and diagnostic agents.

8. The biomolecular complex of claim 2 wherein said biologically active agent is selected from the group consisting of drugs and diagnostic agents.

9. The biomolecular complex of claim 1 wherein said one or more additional eicosapentaenoic acid moieties are selected from the group consisting of eicosapentaenoic acid-containing phosphatidyl serine, eicosapentaenoic acid-containing phosphatidyl ethanolamine and eicosapentaenoic acid-containing phosphatidyl carnitine.

10. The biomolecular complex of claim 2 wherein said one or more additional eicosapentaenoic acid moieties are selected from the group consisting of eicosapentaenoic acid-containing phosphatidyl serine, eicosapentaenoic acid-containing phosphatidyl ethanolamine and eicosapentaenoic acid-containing phosphatidyl carnitine.

11. A lipophilic biomolecular complex comprising:

a) a polycationic carrier selected from the group consisting of poly-lysine, poly-arginine and poly-ornithine containing a minimum of 5 monomeric amino acid units and wherein said polycationic carrier has 2-20 docosahexaenoic acid moieties attached to the terminal amino or guanidino groups of their constitutive monomers, b) a biologically active agent and c) one or more additional docosahexaenoic acid moieties.

12. The biomolecular complex of claim 11 wherein said polycationic carrier has 5 to 50 amino acid residues.

13. The biomolecular complex of claim 11 wherein said biologically active agent is selected from the group consisting of peptides, polypeptides, proteins, enzymes, hormones, growth factors, antigens, antibodies, and polyethylene glycol-derivatized proteins.

14. The biomolecular complex of claim 12 wherein said biologically active agent is selected from the group consisting of peptides, polypeptides, proteins, enzymes, hormones, growth factors, antigens, antibodies, and polyethylene glycol-derivatized proteins.

15. The biomolecular complex of claim 11 wherein said biologically active agent is selected from the group consisting of nucleic acids, oligonucleotides and transfection vectors.

16. The biomolecular complex of claim 12 wherein said biologically active agent is selected from the group consisting of nucleic acids, oligonucleotides and transfection vectors.

17. The biomolecular complex of claim 11 wherein said biologically active agent is selected from the group consisting of drugs and diagnostic agents.

18. The biomolecular complex of claim 12 wherein said biologically active agent is selected from the group consisting of drugs and diagnostic agents.

19. The biomolecular complex of claim 11 wherein said one or more additional docosahexaenoic acid moieties are selected from the group consisting of docosahexaenoic acid-containing phosphatidyl serine, docosahexaenoic acid-containing phosphatidyl ethanolamine and docosahexaenoic acid-containing phosphatidyl carnitine.

20. The biomolecular complex of claim 12 wherein said one or more additional docosahexaenoic acid moieties are selected from the group consisting of docosahexaenoic acid-containing phosphatidyl serine, docosahexaenoic acid-containing phosphatidyl ethanolamine and docosahexaenoic acid-containing phosphatidyl carnitine.

21. The biomolecular complex of claim 11 wherein the complex further comprises a targeting moiety.

22. The biomolecular complex of claim 12 wherein the complex further comprises a targeting moiety.

23. The biomolecular complex of claim 11 wherein said targeting moiety is selected from the group consisting of C fragment of tetanus toxin, alpha-bungarotoxin and nerve growth factor.

24. The biomolecular complex of claim 12 wherein said targeting moiety is selected from the group consisting of C fragment of tetanus toxin, alpha-bungarotoxin and nerve growth factor.